NLRP3 and major depressive disorder: In particular, the NLRP3 inflammasome as well as iNOS have been explored as potential therapeutic targets for the management of MDD [64,90], since inhibition and/or reduced expression of these proteins is related to improvements in depressive-like behaviors in animal models [91,92].